Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Tracking Results of Ablations to Combat AF Registry Generation 2

NCT05111015 · View on ClinicalTrials.gov ↗

Study Summary

The primary objective of the TRAC-AF Registry is to capture real-world safety and effectiveness data on AtriCure devices used to conduct open concomitant and/or hybrid ablation, and management of the LAA concomitant to a cardiac ablation.

Conditions Studied

Interventions

  • DEVICE Open Concomitant Surgical Ablation Procedures
  • DEVICE Hybrid (Convergent) Ablation Procedures
  • DEVICE AtriCure Hybrid Totally Thoracoscopic Ablation Procedures
  • DEVICE AtriCure LAA Exclusion Procedures

Study Locations (20)

Florida

  • Delray Medical Center — Delray Beach
  • University of Florida — Gainesville
  • Orlando Health Heart & Vascular Institute — Orlando
  • St. Joseph's Hospital (BayCare) — Tampa

Arkansas

  • St. Bernards Medical Center — Jonesboro
  • CHI St. Vincent Heart Institute — Little Rock

California

  • Loma Linda University Medical Center — Loma Linda
  • Adventist Heart Institute (St. Helena Hospital) — St. Helena

Michigan

  • University of Michigan — Ann Arbor
  • Corewell Health — Grand Rapids

New York

  • Maimonides Health Heart & Vascular Institute — Brooklyn
  • Vassar Brothers Medical Center — Poughkeepsie

Alabama

  • Huntsville Hospital — Huntsville

Colorado

  • Valley View Hospital — Glenwood Springs

District of Columbia

  • MedStar Washington Hospital — Washington D.C.

Trial Details

FieldValue
Enrollment Target 10,000 participants
Start Date 2013-02
Est. Completion 2030-01

Sponsor

AtriCure

13 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05111015

The ClinicalTrials.gov registry entry for NCT05111015 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 10,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AtriCure, which has 13 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 4 interventions — of which Open Concomitant Surgical Ablation Procedures is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05111015 reports 20 study locations spanning 13 distinct geographic areas — top geographies include Florida, Arkansas, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05111015 about?

NCT05111015 is a clinical study titled "Tracking Results of Ablations to Combat AF Registry Generation 2". The primary objective of the TRAC-AF Registry is to capture real-world safety and effectiveness data on AtriCure devices used to conduct open concomitant and/or hybrid ablation, and management of the LAA concomitant to a cardiac ablation.

What is the current status of trial NCT05111015?

This trial is currently recruiting. The enrollment target is 10,000 participants. The study started on 2013-02. Estimated completion is 2030-01.

What conditions does trial NCT05111015 study?

This clinical trial studies the following conditions: Atrial Fibrillation. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05111015?

The interventions under investigation include: Open Concomitant Surgical Ablation Procedures (DEVICE), Hybrid (Convergent) Ablation Procedures (DEVICE), AtriCure Hybrid Totally Thoracoscopic Ablation Procedures (DEVICE), AtriCure LAA Exclusion Procedures (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05111015?

This trial is sponsored by AtriCure, which has 13 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05111015 being conducted?

This trial has 20 study locations across Alabama, Arkansas, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial